Online inquiry

IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8484MR)

This product GTTS-WQ8484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAL gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001114380.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3683
UniProt ID P20701
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ639MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ13055MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ14858MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ176MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ12578MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ12851MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ2093MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ13847MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1193
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW